Search
Omadacycline
go.drugbank.com/drugs/DB12455ApprovedInvestigationalinfections caused by gram-positive bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA), and by gram-negative, atypical and anaerobic bacteria, including those resistant to currently available … classes of antibiotics and known to cause diseases such as pneumonias, urinary tract infections, skin diseases and blood-borne infections in both the hospital and community settings.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseLumefantrine
go.drugbank.com/drugs/DB06708ApprovedInvestigationalLumefantrine is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with artemether for improved efficacy. … </i> and may be used to treat infections caused by <i>P. falciparum</i> and unidentified <i>Plasmodium</i> species, including infections acquired in chloroquine-resistant areas.
Ziconotide
go.drugbank.com/drugs/DB06283ApprovedInvestigational[L13389] To date, ziconotide is the only calcium channel blocking peptide approved for use by the FDA.[A202835] … [A202829, A202835, A202838, A202841, A202850, A202859, L13389] Ziconotide was granted FDA approval on December 28, 2004 for marketing by TerSera therapeutics LLC. under the name Prialt.
Categories: Compounds used in a research, industrial, or household settingNorgestrel
go.drugbank.com/drugs/DB09389ApprovedNorgestrel is synthetic steroidal progestin that is used in combination with ethinyl estradiol for oral contraception. … Norgestrel is composed of a racemic mixture of two stereoisomers, dextronorgestrel and levonorgestrel. However, only the levorotary enantiomer ([levonorgestrel]) is biologically active.
Mixtures: Lo/Ovral, Lo-ovral-28Categories: Hormonal Contraceptives for Systemic UseItraconazole
go.drugbank.com/drugs/DB01167ApprovedInvestigational[A34257] It is a 1:1:1:1 racemic mixture of four diastereomers, made up of two enantiomeric pairs, each possessing three chiral centers. … First synthesized in the early 1980s, itraconazole is a broad-spectrum triazole antifungal agent used to treat a variety of infections.
Categories: Antimycotics for Systemic Use, Antiinfectives for Systemic UseUmbralisib
go.drugbank.com/drugs/DB14989ApprovedInvestigationalWithdrawnIt was marketed as Ukoniq by TG Therapeutics and has been approved for the treatment of relapsing and refractory marginal cell lymphoma and follicular lymphoma in adults. … Treatment options then become limited, and alternate treatments for the lymphoma are required to control disease progression.
Phenindamine
go.drugbank.com/drugs/DB01619ApprovedAntihistamines such as phenindamine appear to compete with histamine for histamine H1- receptor sites on effector cells. … It is used to treat sneezing, runny nose, itching, watery eyes, hives, rashes, itching, and other symptoms of allergies and the common cold.
Categories: Antihistamines for Systemic UseTisagenlecleucel
go.drugbank.com/drugs/DB13881ApprovedInvestigationalTisagenlecleucel is a CD19-directed genetically modified autologous T cell immunotherapy, or a CAR-T cell therapy for B-cell acute lymphoblastic leukemia. … It was granted approval by FDA in August 2017 under the market name Kymriah.
Categories: Genetically-modified Autologous T CellsSynonyms: Tisagenlecleucel-T, CAR.CD19-Redirected T cellsInfigratinib
go.drugbank.com/drugs/DB11886ApprovedInvestigationalWithdrawn[A235174] On May 28, 2021, the FDA granted accelerated approval to infigratinib - under the market name Truseltiq - for the treatment of previously treated, unresectable locally advanced or metastatic … [L34304] The FDA later announced the final withdrawal of the approval of infigratinib for this indication on May 16, 2024: This decision was based on the sponsor's request due to clinical trial recruitment
Triclabendazole
go.drugbank.com/drugs/DB12245ApprovedInvestigationalTriclabendazole was previously used in the treatment of fascioliasis in livestock, but is now approved for human use. … Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.